DaVita’s first quarter results were met with a strongly positive market reaction, reflecting operational execution and ongoing cost control. Management attributed the quarter’s outperformance to balanced gains across treatment volume, revenue per treatment, and cost management, aided by productivity improvements and favorable patient outcomes. CEO Javier Rodriguez highlighted the continued momentum of the company’s Integrated Kidney Care (IKC) business, which delivered year-over-year improvements in quality and cost metrics within the CMS Comprehensive Kidney Care Contracting program. Management also emphasized investments in technology and data infrastructure as foundational to clinical and operational excellence.
Is now the time to buy DVA? Find out in our full research report (it’s free for active Edge members).
DaVita (DVA) Q1 CY2026 Highlights:
- Revenue: $3.42 billion vs analyst estimates of $3.35 billion (6% year-on-year growth, 2.1% beat)
- Adjusted EPS: $2.87 vs analyst estimates of $2.33 (23.2% beat)
- Adjusted EBITDA: $659.8 million vs analyst estimates of $610.7 million (19.3% margin, 8.1% beat)
- Management raised its full-year Adjusted EPS guidance to $14.65 at the midpoint, a 2.4% increase
- Operating Margin: 14.1%, in line with the same quarter last year
- Sales Volumes were flat year on year (-1.6% in the same quarter last year)
- Market Capitalization: $12.77 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From DaVita’s Q1 Earnings Call
- Kevin Fischbeck (Bank of America) asked how weather and flu season affected volume and whether improved mortality was sustainable. CFO Joel Ackerman explained weather and flu were in line with forecasts, and the improved mortality was likely driven by underlying trends rather than seasonal factors.
- Andrew Mok (Barclays) inquired about DaVita’s ability to capture market share due to Fresenius clinic closures. CEO Javier Rodriguez noted competitive efforts to retain patients but said DaVita is actively making its network accessible to new patients and physicians.
- Pito Chickering (Deutsche Bank) asked how new patient admissions and Fresenius transfers would impact treatment growth throughout the year. Ackerman projected that most transfers would occur by the second quarter and expected normalized treatments per day to increase steadily.
- A.J. Rice (UBS) questioned whether declines in health benefit and pharmaceutical costs were expected or unusually positive. Ackerman confirmed these were typical seasonal changes with no unusual items.
- Ryan Langston (TD Cowen) sought clarification on free cash flow guidance remaining unchanged despite higher operating income. Ackerman responded that free cash flow is subject to more variability, so guidance was not adjusted.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will focus on (1) evidence that productivity improvements and digital initiatives are translating into sustained operating margin gains, (2) the scale and timing of patient transfers from competitor clinic closures, and (3) the impact of ACA enrollment mix on revenue per treatment. Additionally, we will watch for updates on DaVita’s AI deployment and broader adoption of value-based care models as potential drivers of future performance.
DaVita currently trades at $195.99, up from $157.04 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
